\begin{longtable}{lccccccccc}
\caption{Inference for Day 18antibody marker covariate-adjusted correlates of risk of HPV in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*} \\ 
   \hline
 
         \multicolumn{1}{l}{IARC_HPV} & \multicolumn{1}{c}{Tertile}   & \multicolumn{1}{c}{No. cases /}   & \multicolumn{1}{c}{Attack}   & \multicolumn{2}{c}{Haz. Ratio}                     & \multicolumn{1}{c}{P-value}   & \multicolumn{1}{c}{Overall P-}      & \multicolumn{1}{c}{Overall q-}   & \multicolumn{1}{c}{Overall} \\ 
         \multicolumn{1}{l}{Immunologic Marker}            & \multicolumn{1}{c}{}          & \multicolumn{1}{c}{No. at-risk**} & \multicolumn{1}{c}{rate}   & \multicolumn{1}{c}{Pt. Est.} & \multicolumn{1}{c}{95\% CI} & \multicolumn{1}{c}{(2-sided)} & \multicolumn{1}{c}{value***} & \multicolumn{1}{c}{value $\dagger$} & \multicolumn{1}{c}{FWER} \\ 
         \hline
 
      Anti L1, L2 IgG HPV6 (AU/ml) & Lower & 12/1,012 & 0.0119 & 1 & N/A & N/A & 0.327 & 0.810 & 1.000 \\ 
   & Middle & 7/1,011 & 0.0069 &  &  &  &     &  &  \\ 
   & Upper & 6/1,000 & 0.0060 & 0.62 & (0.27-1.43) & 0.266 &     &  &  \\ 
  Anti L1, L2 IgG HPV11 (AU/ml) & Lower & 9/1,029 & 0.0087 & 1 & N/A & N/A & 0.810 & 0.810 & 1.000 \\ 
   & Middle & 9/  999 & 0.0090 &  &  &  &     &  &  \\ 
   & Upper & 7/  995 & 0.0070 & 1.13 & (0.45-2.83) & 0.796 &     &  &  \\ 
  Anti L1, L2 IgG HPV16 (IU/ml) & Lower & 11/1,030 & 0.0107 & 1 & N/A & N/A & 0.675 & 0.810 & 1.000 \\ 
   & Middle & 7/  999 & 0.0070 &  &  &  &     &  &  \\ 
   & Upper & 7/  994 & 0.0070 & 0.69 & (0.27-1.78) & 0.442 &     &  &  \\ 
  Anti L1, L2 IgG HPV18 (IU/ml) & Lower & 14/1,007 & 0.0139 & 1 & N/A & N/A & 0.081 & 0.405 & 0.729 \\ 
   & Middle & 3/1,015 & 0.0030 &  &  &  &     &  &  \\ 
   & Upper & 9/1,001 & 0.0090 & 0.24 & (0.07-0.83) & 0.025 &     &  &  \\ 
  Anti L1, L2 IgG HPV31 (AU/ml) & Lower & 16/1,834 & 0.0087 & 1 & N/A & N/A & 0.798 & 0.810 & 1.000 \\ 
   & Middle & 6/  598 & 0.0100 &  &  &  &     &  &  \\ 
   & Upper & 4/  591 & 0.0068 & 1.24 & (0.48-3.18) & 0.658 &     &  &  \\ 
  Anti L1, L2 IgG HPV33 (AU/ml) & Lower & 25/2,961 & 0.0084 & 1 & N/A & N/A & 0.521 &     &     \\ 
   & Middle & 1/   62 & 0.0161 &  &  &  &     &  &  \\ 
   & Upper & NA/   NA &      & 2.14 & (0.21-21.83) & 0.521 &     &  &  \\ 
  Anti L1, L2 IgG HPV45 (AU/ml) & Lower & 24/2,524 & 0.0095 & 1 & N/A & N/A & 0.228 &     &     \\ 
   & Middle & 2/  499 & 0.0040 &  &  &  &     &  &  \\ 
   & Upper & NA/   NA &      & 0.45 & (0.12-1.65) & 0.228 &     &  &  \\ 
  Anti L1, L2 IgG HPV52 (AU/ml) & Lower & 23/2,565 & 0.0090 & 1 & N/A & N/A & 0.620 &     &     \\ 
   & Middle & 3/  458 & 0.0066 &  &  &  &     &  &  \\ 
   & Upper & NA/   NA &      & 0.75 & (0.24-2.37) & 0.620 &     &  &  \\ 
  Anti L1, L2 IgG HPV58 (AU/ml) & Lower & 22/2,633 & 0.0084 & 1 & N/A & N/A & 0.626 &     &     \\ 
   & Middle & 4/  390 & 0.0103 &  &  &  &     &  &  \\ 
   & Upper & NA/   NA &      & 1.31 & (0.44-3.92) & 0.626 &     &  &  \\ 
  Anti L1, L2 IgG Score & Lower & 11/1,008 & 0.0109 & 1 & N/A & N/A & 0.142 &     &     \\ 
   & Middle & 4/1,020 & 0.0039 &  &  &  &     &  &  \\ 
   & Upper & 10/  995 & 0.0101 & 0.38 & (0.13-1.08) & 0.069 &     &  &  \\ 
   \hline
\hline
\label{tab:CoR_univariable_logistic_cat_pretty_IARC_HPV}
\end{longtable}
